Pulmonx Corporation (NASDAQ:LUNG) Receives $6.81 Average Price Target from Analysts

Pulmonx Corporation (NASDAQ:LUNG) has earned an average recommendation of “Hold” from the ten analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $6.8071.

A number of equities analysts have recently issued reports on LUNG shares. D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Finally, Lake Street Capital dropped their price target on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, October 28th.

Pulmonx Price Performance

Shares of NASDAQ:LUNG opened at $1.85 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. Pulmonx has a 52 week low of $1.31 and a 52 week high of $9.37. The firm has a market cap of $76.31 million, a PE ratio of -1.31 and a beta of 0.10. The firm’s fifty day moving average is $2.03 and its 200-day moving average is $1.96.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. The business had revenue of $21.50 million during the quarter, compared to the consensus estimate of $20.78 million. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%. Sell-side analysts predict that Pulmonx will post -1.55 earnings per share for the current year.

Institutional Trading of Pulmonx

A number of large investors have recently bought and sold shares of the business. Vestal Point Capital LP bought a new position in shares of Pulmonx in the 3rd quarter worth about $1,345,000. Bank of America Corp DE grew its stake in Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after purchasing an additional 407,971 shares during the period. GSA Capital Partners LLP increased its holdings in Pulmonx by 78.3% in the third quarter. GSA Capital Partners LLP now owns 755,467 shares of the company’s stock worth $1,224,000 after purchasing an additional 331,742 shares in the last quarter. Norges Bank bought a new stake in Pulmonx in the second quarter worth approximately $392,000. Finally, Citadel Advisors LLC lifted its stake in Pulmonx by 213.5% in the third quarter. Citadel Advisors LLC now owns 217,176 shares of the company’s stock valued at $352,000 after buying an additional 147,904 shares during the period. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.